Study guide
15.3 Medication-Induced & Hematologic Atypical Wounds
Certified Wound Specialist Physician CWSP
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the CWSP Exam
2 Chapter 1: Integumentary Anatomy & Wound Healing Biology
1.1 Skin Anatomy, Microstructure & Epidermal-Dermal Barrier Function 1.2 Acute vs Chronic Wound Healing Phases & Cellular Kinetics 1.3 Extracellular Matrix Composition, Collagen Architecture & MMP Regulation
3 Chapter 2: Musculoskeletal & Neurologic Anatomy
2.1 Musculoskeletal Anatomy of the Leg & Foot 2.2 Neuroanatomy & Nerve Physiology for Wound Care
4 Chapter 3: Cell Signaling, Biofilm & Barriers to Healing
3.1 Growth Factors, Cytokines & Angiogenic Pathways 3.2 Biofilm Microbiology, Quorum Sensing & Phenotypic Resistance 3.3 Cellular Senescence, Hypoxia & Inflammatory Arrest 3.4 Metabolic, Steroid & Nutritional Impairments in Wound Healing
5 Chapter 4: Patient Evaluation & Vascular Diagnostics
4.1 Comprehensive Patient & Periwound Physical Examination 4.2 Noninvasive Macrovascular Hemodynamics: ABI, TBI & Segmental Pressures 4.3 Microvascular Perfusion Diagnostics: TcPO2, SPP & Near-Infrared Spectroscopy 4.4 Diagnostic Angiography, Duplex Ultrasonography & Angiosome Concepts
6 Chapter 5: Pain, Risk, Functional & Nutrition Assessment
5.1 Wound Pain Assessment 5.2 Risk Assessment Tools & Risk Stratification 5.3 Functional & Cognitive Assessment 5.4 Nutrition Screening & Assessment
7 Chapter 6: Imaging, Biopsy, Atypical Wounds & Neuropathy
6.1 Musculoskeletal Imaging for Osteomyelitis & Deep Space Infections 6.2 Diagnostic Tissue Biopsy, Culture Techniques & Quantitative Microbiology 6.3 Diagnostic Differential of Atypical & Malignant Ulcerations 6.4 Comprehensive Diabetic Peripheral Neuropathy & Biomechanical Assessment
8 Chapter 7: Wound Bed Preparation, Debridement, Dressings & Topical Agents
7.1 TIME Principle & Wound Bed Preparation Framework 7.2 Surgical, Sharp, Enzymatic, Autolytic & Biosurgical Debridement Modalities 7.3 Advanced Wound Dressings, Exudate Control & Moisture Balance 7.4 Topical Agents: Antiseptics, Antibiotics & Active Topicals
9 Chapter 8: Cellular & Tissue-Based Products, NPWT & Hyperbaric Oxygen
8.1 Cellular, Acellular & Matrix-Like Advanced Biologics (CTPs) 8.2 Negative Pressure Wound Therapy (NPWT) & Instillation Protocols 8.3 Hyperbaric Oxygen Therapy (HBOT): Mechanisms, Indications & Safety
10 Chapter 9: Biophysical Technologies: Electrical Stimulation & Ultrasound
9.1 Electrical Stimulation for Wound Healing 9.2 Therapeutic Ultrasound in Wound Care
11 Chapter 10: Revascularization, Antimicrobial Stewardship & Offloading
10.1 Revascularization for Limb Salvage 10.2 Systemic Antimicrobial Stewardship & Deep Infection Management 10.3 Mechanical Offloading, Pressure Redistribution & Total Contact Casting
12 Chapter 11: Surgical Closure & Healing Complications
11.1 Surgical Closure, Skin Grafts, Flaps & Amputation Levels 11.2 Managing Complications: Bleeding, Allergy, Adverse Events & Scarring
13 Chapter 12: Nutrition Therapy & Case Review
12.1 Nutrition Therapy for Wound Healing 12.2 Case Review: Synthesizing Data, Outliers & Prognosis
14 Chapter 13: Diabetic & Ischemic Lower-Extremity Wounds
13.1 Diabetic Foot Ulcers: Pathophysiology, Staging & Limb Salvage 13.2 Peripheral Arterial Disease & Ischemic Extremity Ulcerations 13.3 Mixed Arterial-Venous Disease & Complex Diagnostic Dilemmas
15 Chapter 14: Venous Disease, Pressure Injuries, Lymphedema & Edema
14.1 Venous Leg Ulcers, Chronic Venous Insufficiency & Compression 14.2 Pressure Injuries: NPIAP Staging, DTPI & Prevention 14.3 Lymphedema, Phlebolymphedema & Complete Decongestive Therapy 14.4 Edema: Systemic vs. Local Causes
16 Chapter 15: Inflammatory, Calcific, Medication-Induced & Dermatologic Wounds
15.1 Autoimmune & Inflammatory Ulcerations: Pyoderma Gangrenosum & Vasculitis 15.2 Calciphylaxis & Radiation Tissue Injury 15.3 Medication-Induced & Hematologic Atypical Wounds 15.4 Dermatologic Conditions That Cause or Complicate Wounds
17 Chapter 16: Traumatic Wounds, Burns & Frostbite
16.1 Traumatic Wounds: Lacerations, Bites, Degloving & Open Fractures 16.2 Thermal Burns & Frostbite
18 Chapter 17: Surgical, Infectious & Pediatric Wounds
17.1 Surgical Wounds, Surgical Site Infection & Dehiscence 17.2 Infectious Causes of Wounds: Necrotizing, Mycobacterial, Fungal & Other Infections 17.3 Pediatric Wound Care
19 Chapter 18: Reimbursement, Regulation & Documentation
18.1 CPT Coding, Modifiers & Documentation for Debridement and Biologics 18.2 Regulatory Compliance, CMS Quality Programs & Hospital-Acquired Conditions 18.3 Documentation, Legal Concepts & Confidentiality
20 Chapter 19: Ethics, Adherence, Epidemiology & Evidence-Based Practice
19.1 Clinical Ethics, Informed Consent & Palliative Wound Management 19.2 Patient Adherence & Psychosocial Care 19.3 Epidemiology of Chronic Wounds 19.4 Research Literacy, Evidence-Based Medicine & Quality Improvement
15.3 Medication-Induced & Hematologic Atypical Wounds
Key Takeaways Explain This Topic AI
Warfarin-induced skin necrosis appears about 3 to 5 days after starting warfarin, often without heparin overlap, in fatty areas such as the breasts, thighs, and buttocks; stop warfarin, give vitamin K, anticoagulate with heparin, and consider protein C concentrate or plasma.
Heparin-induced thrombocytopenia can cause skin necrosis at injection sites, typically 5 to 10 days after heparin exposure; assess with the 4Ts score, stop all heparin, and start a non-heparin anticoagulant such as argatroban, bivalirudin, fondaparinux, or a direct oral anticoagulant.
Hydroxyurea can cause painful ulcers around the malleoli during long-term therapy that often heal only after the drug is reduced or stopped, while levamisole-adulterated cocaine causes retiform purpura and necrosis of the ears and cheeks, often with neutropenia and positive ANCA.
Hematologic causes of ulcers include sickle cell disease (malleolar ulcers), cryoglobulinemia, polycythemia vera and essential thrombocythemia, livedoid vasculopathy, and inherited or acquired clotting disorders; send cryoglobulin samples warm at 37°C.
Chemotherapy extravasation needs agent-specific care: dexrazoxane for anthracyclines, hyaluronidase with warm compresses for vinca alkaloids, and phentolamine for vasopressor extravasation.
Last updated: September 2026
15.3 Medication-Induced & Hematologic Atypical Wounds
Core Clinical Principle: When a wound does not match the usual venous, arterial, pressure, or diabetic patterns, look at the medication list and the blood. Drugs and blood disorders can cause skin necrosis within days or chronic ulcers that heal only when the cause is removed.
The CWSP outline lists atypical wounds, including malignancy and medication-induced wounds, under Etiological Considerations. Malignant wounds and inflammatory ulcers are covered in their own sections; this section focuses on drugs and hematologic disease.
Medication-Induced Skin Necrosis
Condition Timing and Setting Appearance Management
Warfarin-induced skin necrosis Days 3 to 5 after starting warfarin, often with a loading dose and no heparin overlap; linked to protein C deficiency Painful red patches that become hemorrhagic bullae and black necrosis in fatty areas (breasts, thighs, buttocks, abdomen) Stop warfarin, give vitamin K, anticoagulate with heparin, consider protein C concentrate or fresh frozen plasma; surgical care of necrosis
Heparin-induced thrombocytopenia (HIT) skin necrosis Usually 5 to 10 days after heparin exposure (sooner with recent exposure) Necrosis at subcutaneous injection sites; platelet fall of more than 50%; venous or arterial thrombosis 4Ts score, stop all heparin including flushes, start a non-heparin anticoagulant; confirm with PF4 antibody and functional assays
Vasopressor-related necrosis High-dose norepinephrine, vasopressin, or other pressors in shock Symmetric acral necrosis of fingers, toes, ears, nose Minimize pressor dose when possible; allow demarcation before amputation
Nicolau syndrome (embolia cutis medicamentosa) Minutes to hours after intramuscular or intra-articular injection Severe pain, livedoid patch, then necrosis at the injection site Supportive wound care, pain control, debridement when demarcated
Drug-Associated Ulcers and Wounds
Hydroxyurea: Painful, shallow ulcers around the malleoli or on the legs during long-term therapy for myeloproliferative disorders or sickle cell disease. They resist standard care and often heal only after dose reduction or stopping the drug, in consultation with hematology.
Methotrexate: Toxicity can erode psoriatic plaques or cause mucosal and skin ulcers, especially with kidney impairment or dosing errors (daily instead of weekly); treat with leucovorin rescue.
Levamisole-adulterated cocaine: Retiform purpura and necrosis of the ears, cheeks, and nose , often with neutropenia and positive ANCA (commonly atypical patterns). Stopping cocaine use is essential.
Xylazine-associated wounds: Xylazine, a veterinary sedative mixed into the illicit fentanyl supply, is linked to severe wounds at and away from injection sites. The FDA issued a warning in 2022, and the federal government declared fentanyl combined with xylazine an emerging threat in 2023. Care focuses on nonjudgmental wound care, harm reduction, and treatment of substance use; naloxone reverses opioids but not xylazine.
Nicorandil: Associated with painful oral, anal, and skin ulcers that heal after stopping the drug (used mainly outside the United States).
Drugs that impair healing: Systemic corticosteroids; VEGF inhibitors such as bevacizumab (labeling advises stopping at least 28 days before elective surgery and waiting at least 28 days after surgery and until the wound is healed); mTOR inhibitors (sirolimus, everolimus); antiproliferative chemotherapy; and some biologic immunosuppressants.
Extravasation Injuries
Agent Type Examples Specific Measures
Anthracyclines Doxorubicin, daunorubicin Stop infusion, aspirate, cold compresses; intravenous dexrazoxane within 6 hours (stop cooling beforehand)
- Vinca alkaloids Vincristine, vinblastine Hyaluronidase injection and warm compresses to disperse the drug
- Vasopressors Norepinephrine, dopamine Local phentolamine injection
Other irritants and vesicants Calcium salts, potassium, hypertonic dextrose, contrast media, some antibiotics Stop infusion, elevate, consider hyaluronidase; surgical consult for compartment symptoms or skin loss
Hematologic Causes of Ulcers
Condition Key Features Workup and Treatment
Sickle cell disease Painful ulcers over the malleoli, most common in HbSS; slow healing and frequent recurrence Hemoglobin electrophoresis; compression if perfusion allows, wound care, hematology co-management (transfusion strategies, disease-modifying therapy)
Thalassemia and hereditary spherocytosis Leg ulcers from chronic hemolysis and anemia CBC, smear, hemolysis markers
Cryoglobulinemia Type I (monoclonal): occlusive retiform purpura and acral necrosis; mixed types II and III: vasculitis, often with hepatitis C Cryoglobulins drawn and transported warm at 37°C , complement levels, hepatitis C testing, serum protein electrophoresis
Polycythemia vera and essential thrombocythemia Erythromelalgia, acral ischemia, ulcers CBC, JAK2 mutation testing; low-dose aspirin, cytoreduction
Livedoid vasculopathy Painful recurrent ulcers around the ankles that heal as white stellate scars (atrophie blanche), often worse in summer Biopsy showing vessel thrombi without true vasculitis; thrombophilia testing; antiplatelet or anticoagulant therapy (for example, rivaroxaban off-label)
Protein C or S deficiency, antiphospholipid syndrome, DIC Purpura fulminans, retiform purpura, necrosis Coagulation studies, antiphospholipid antibodies, protein C and S levels; anticoagulation and treatment of the cause
Retiform Purpura: A Red Flag
Net-like, branching purpura with necrosis signals blocked small vessels from thrombosis, emboli, calciphylaxis, cryoglobulins, or vasculitis. It calls for prompt biopsy (including the purpuric edge), coagulation and hematologic studies, and a medication and drug use history.
- Clinical Traps
- Trap 1: Continuing Warfarin Through Early Necrosis
New painful purpura in fatty tissue days after starting warfarin is an emergency. Stop warfarin, give vitamin K, and switch to heparin.
Trap 2: Debriding a Hydroxyurea Ulcer Without Addressing the Drug
Repeated debridement and advanced dressings rarely help while the patient remains on hydroxyurea. Discuss dose changes with hematology.